Table. 5.

Strategies for preventing fungal infections in solid organ transplantations

Characteristic Kidney (n=31) Liver (n=25) Heart (n=8) Lung (n=8)
Pneumocystis jirovecii prevention
None 1 (3) 1 (4) 0 0
Prophylaxis 30 (97) 24 (96) 8 (100) 8 (100)
Trimethoprim/sulfamethoxazole (oral) 30 (97) 24 (96) 8 (100) 8 (100)
Duration of prophylaxis (mo) 6 (3‒12) 6 (2‒12) 12 (6‒12) Lifelong (12‒lifelong)
Fungus prevention
None 18 (58) 6 (24) 3 (38) 0
Prophylaxis 13 (42) 19 (76) 5 (63) 8 (100)
Nystatin (oral) 7 (23) 0 4 (50) 0
Fluconazole (oral) 6 (19) 10 (40) 0 0
Itraconazole (oral) 0 5 (20) 1 (13) 4 (50)
Itraconazole (oral)+LAMB (intravenous) (1 mg/kg) 0 1 (4) 0 0
LAMB (intravenous) (1 mg/kg) 0 3 (12) 0 0
Itraconazole (oral)+sGM monitoring 0 0 0 1 (13)
Itraconazole (oral)+AMB nebulizer+sGM monitoring 0 0 0 1 (13)
Voriconazole (oral)+sGM monitoring 0 0 0 2 (25)
Duration of prophylaxis (mo) 1 (0.5‒6) 1 (0.13‒3) 1 (1‒6) 6 (3‒6)
Duration of sGM monitoring (mo) 0 0 0 12 (3‒12)

Values are presented as number (%) or median (range).

LAMB, liposomal amphotericin B; sGM, serum galactomannan; AMB, amphotericin B.

Korean J Transplant 2022;36:212~220 https://doi.org/10.4285/kjt.22.0036
© Korean Journal of Transplantation